Abstract

Background: Endothelial dysfunction is closely associated with increased circulating levels of endothelial microparticles (EMPs) in patients with end-stage renal disease (ESRD). As arterial damage is a major contributor to cardiovascular mortality, we examined whether or not circulating levels of EMPs could predict outcome in ESRD. Methods: This prospective study included 81 stable hemodialyzed patients with ESRD (age 59±14 yr; 63% male; follow-up 57 months). Baseline plasma microparticles (MPs) levels, cell origin and reproducibility were analyzed by flow cytometry. The primary end-point was the occurrence of any death. Secondary end-points included cardiovascular death and occurrence of major adverse cardiovascular events (MACE). Results: Non-survivors (n=19) were older (70.6±9.2, vs. 55.1±13.2 y, p<0.001) and were characterized by lower diastolic blood pressure (70.8±10.5 vs. 80±12.4 mmHg, p<0.01), higher levels of hsCRP (6.9±4.4 vs. 5.0±4.3 mg/L, p<0.05) and endothelial CD31+CD41- EMPs (1822±1516 vs. 934±207 ev/ μ l, p<0.001), whereas other MPs subtypes were not different. Mutivariate Cox analysis demonstrated that baseline EMPs levels independently predicted all-cause death (HR=4.0 [1.2–13.0] per log unit, p=0.02), cardiovascular mortality (HR=8.81 [2.4 –31.8], p<0.001) and MACE (HR=3.28 [1.2 – 8.9], p<0.01) after adjustment for age, traditional cardiovascular risk factors, medications and biological parameters. ROC curve analysis showed that baseline EMPs levels correctly predicted all-causes and cardiovascular mortality (AUC: 0.80±0.008 and 0.83±0.008 respectively, p<0.001 for all). EMP baseline level > 710 event/ μ L correctly identified subsequent death with a sensitivity of 92% and a specificity of 63%. Kaplan-Meier analysis revealed that survival of patients with EMPs levels above median was worse than other patients (p<0.01, log rank analysis), whereas platelet MPs levels did not affect outcome. Conclusions: Increased circulating levels of endothelial microparticles is a robust independent predictor of all-causes and mainly cardiovascular mortality in patients with ESRD and could help identify asymptomatic patients at higher risk of developing cardiovascular diseases and adjust therapy.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call